Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies

[1]  M. Saruta,et al.  Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD) , 2022, Journal of Gastroenterology.

[2]  Harminder Singh,et al.  AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. , 2021, Gastroenterology.

[3]  Julia J. Liu.  Disparity in the Care of black Inflammatory Bowel Disease Patients. , 2021, Inflammatory bowel diseases.

[4]  E. Loftus,et al.  Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. , 2020, Gastroenterology.

[5]  E. Barnes,et al.  Trends and Characteristics of Clinical Trials Participation for Inflammatory Bowel Disease in the United States: A Report From IBD Partners , 2020, Crohn's & colitis 360.

[6]  J. Korzenik,et al.  South Asian Patients With Inflammatory Bowel Disease in the United States Demonstrate More Fistulizing and Perianal Crohn Phenotype. , 2020, Inflammatory bowel diseases.

[7]  Siddharth Singh,et al.  AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.

[8]  E. Rupniewska,et al.  Real‐world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review , 2019, Journal of clinical pharmacy and therapeutics.

[9]  A. Hartzema,et al.  Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. , 2019, Inflammatory bowel diseases.

[10]  K. Sugano,et al.  Evidence-based clinical practice guidelines for inflammatory bowel disease , 2018, Journal of Gastroenterology.

[11]  C. Kin,et al.  Market share and costs of biologic therapies for inflammatory bowel disease in the USA , 2018, Alimentary pharmacology & therapeutics.

[12]  Christopher F. Martin,et al.  Asians Have More Perianal Crohn Disease and Ocular Manifestations Compared with White Americans , 2017, Inflammatory Intestinal Diseases.

[13]  C. Selinger,et al.  Medication adherence in inflammatory bowel disease , 2017, Intestinal research.

[14]  J. Im.  Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease? , 2017, Intestinal research.

[15]  A. López-Sanromán,et al.  Management of complex perianal Crohn’s disease , 2016, Annals of gastroenterology.

[16]  T. Mikuls,et al.  Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[17]  Judy H. Cho,et al.  Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[18]  R. Cross,et al.  Racial and Ethnic Minorities with Inflammatory Bowel Disease in the United States: A Systematic Review of Disease Characteristics and Differences , 2016, Inflammatory bowel diseases.

[19]  D. Owczarek,et al.  Diet and nutritional factors in inflammatory bowel diseases. , 2016, World journal of gastroenterology.

[20]  S. Dalal,et al.  What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. , 2015, Gastroenterology & hepatology.

[21]  Deena J. Chisolm,et al.  Racial Disparities in Readmission, Complications, and Procedures in Children with Crohn's Disease , 2015, Inflammatory bowel diseases.

[22]  D. Sachar,et al.  Race and Fistulizing Perianal Crohn’s Disease , 2015, Journal of clinical gastroenterology.

[23]  R. Odze.  A contemporary and critical appraisal of ‘indeterminate colitis’ , 2015, Modern Pathology.

[24]  W. Olson,et al.  Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy , 2014, Journal of medical economics.

[25]  V. Durand.  Diagnostic criteria and epidemiology. , 2014 .

[26]  R. Panaccione.  Mechanisms of inflammatory bowel disease. , 2013, Gastroenterology & hepatology.

[27]  L. Peyrin-Biroulet,et al.  Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory Bowel Diseases.

[28]  J. Sewell,et al.  Systematic Review: The Role of Race and Socioeconomic Factors on IBD Healthcare Delivery and Effectiveness , 2013, Inflammatory bowel diseases.

[29]  C. Beauchemin,et al.  Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database , 2013, BMC Gastroenterology.

[30]  C. Carter,et al.  Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease , 2012, Patient preference and adherence.

[31]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[32]  Ning Zhou,et al.  Inflammatory bowel disease unclassified , 2011, Journal of Zhejiang University SCIENCE B.

[33]  Marie T. Brown,et al.  Medication adherence: WHO cares? , 2011, Mayo Clinic proceedings.

[34]  G. Hirschfield,et al.  Pathogenesis of cholestatic liver disease and therapeutic approaches. , 2010, Gastroenterology.

[35]  S. Brant,et al.  NOD2 Mutations and Anti-Saccharomyces cerevisiae Antibodies Are Risk Factors for Crohn's Disease in African Americans , 2010, The American Journal of Gastroenterology.

[36]  S. Brant,et al.  Patient trust‐in‐physician and race are predictors of adherence to medical management in inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[37]  A. Repaka,et al.  Crohn's Disease in an African-American Population , 2008, The American journal of the medical sciences.

[38]  P. Lakatos.  Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.

[39]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[40]  T. Matsui,et al.  Crohn’s Disease in Japan: Diagnostic Criteria and Epidemiology , 2000 .

[41]  A. Zinsmeister,et al.  Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. , 1998, Gastroenterology.

[42]  D. Fraser,et al.  Epidemiological data of Crohn's disease in Israel: etiological implications. , 1989, Public health reviews.

[43]  J. Garisch,et al.  Inflammatory bowel disease Cape Town, 1975-1980 , 1983 .